CNS Pharmaceuticals reports cash position of $14M as of February 26

CNS Pharmaceuticals (CNSP) provided an update on its current cash position and discussed the completion of its recent initiative to maintain its listing on the NASDAQ Capital Market. “As we kick off 2025, the Company has never been fundamentally stronger. Our team conducted a global trial of Berubicin, and we remain on track to announce our primary data analysis in the first half of 2025,” commented John Climaco, CEO. “On the financial front, we now have the necessary capital to fund planned operations into the first quarter of 2026. To be precise, this means not just continuing and expanding our work based on the aforementioned Berubicin data but also charging toward our goal of commencing our TPI 287 clinical program by consenting our first patient before the end of the year. We have begun what we believe will be the most transformational year in the history of the Company and have high hopes that the GBM community and our stakeholders will be celebrating this, along with the patients impacted by this disease, in the very near term. Additionally, maintaining our listing on Nasdaq is a top priority for the Company. Given our expected primary analysis in the first half of 2025 and our plans to advance TPI 287, we believe our listing on NASDAQ supports the strength of the company we believe will exist in the second half of 2025 following the completion of key milestones. We are executing to the best of our abilities to remain listed and will continue to do so.” As of February 26, 2025, the Company’s current cash position has increased to $14M. Based on current projections, management believes the current cash on hand is sufficient to fund operations into 2026, including the expected upcoming catalytic milestones. As previously announced, the Company implemented a reverse stock split of the Company’s common stock in order to regain compliance with NASDAQ’s minimum bid price requirement.